



(51) International Patent Classification:
C07K 14/015 (2006.01) C12N 7/00 (2006.01)
C12N 15/864 (2006.01)

(21) International Application Number:
PCT/US2024/035946

(22) International Filing Date:
28 June 2024 (28.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/524,265 30 June 2023 (30.06.2023) US

(71) Applicant: **R.P. SCHERER TECHNOLOGIES, LLC**
[US/US]; 112 North Curry Street, Carson City, Nevada
89703 (US).

(72) Inventors: **KONDRAGUNTA, Bhargavi**; c/o R.P.
SCHERER TECHNOLOGIES, LLC, 112 North Curry
Street, Carson City, Nevada 89703 (US). **WANG, Ruigong**;
c/o R.P. SCHERER TECHNOLOGIES, LLC, 112 North

Curry Street, Carson City, Nevada 89703 (US). **PAUL, Sid-
dhartha**; c/o R.P. SCHERER TECHNOLOGIES, LLC, 112
North Curry Street, Carson City, Nevada 89703 (US).


(74) Agent: **JONES, J. Mitchell**; Casimir Jones, S.C., 2275
Deming Way, Ste 310, Middleton, Wisconsin 53562 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: IMPROVED ADENO-ASSOCIATED VIRUS VECTORS

FIG. 1



(57) Abstract: The present invention relates AAV genomes, vectors and nucleic acids containing variant capsid protein sequences that allow for increased titer, along with improved packing during recombinant AAV vector particle production. Titers improved several fold, without a similar increase in residual packaged hCDNA, along with maintaining percent full capsid ratio. In addition viral proteins expression and ratios remained unchanged with the variants.

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*